Atara Biotherapeutics

OverviewSuggest Edit

Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Atara operates through the business of developing and commercializing therapeutics segment.

TypePublic
Founded2012
HQSouth San Francisco, US
Websiteatarabio.com
Employee Ratings3.2
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)393(+27%)
Job Openings47
Share Price (Nov 2020)$23 (+4%)
Cybersecurity ratingDMore

Key People/Management at Atara Biotherapeutics

Pascal Touchon

Pascal Touchon

President and Chief Executive Officer, Director
Eric Dobmeier

Eric Dobmeier

Director
Roy D. Baynes

Roy D. Baynes

Director
Ron Renaud

Ron Renaud

Chairman of the Board
Jakob Dupont

Jakob Dupont

EVP, Head of Global Research & Development
Matthew Fust

Matthew Fust

Director, Audit Committee Chair
Show more

Atara Biotherapeutics Office Locations

Atara Biotherapeutics has offices in South San Francisco, Aurora, New York, Thousand Oaks and in 1 other location
South San Francisco, US (HQ)
Building 83, 611 Gateway Blvd #900
Aurora, US
12635 E Montview Blvd #280
New York, US
135 E 57th St 14th Floor
Thousand Oaks, US
2430 Conejo Spectrum St
Zug, CH
Baarerstrasse 14
Show all (5)

Atara Biotherapeutics Financials and Metrics

Atara Biotherapeutics Revenue

USD

Net income (Q2, 2020)

(77.5m)

EBIT (Q2, 2020)

(78.0m)

Market capitalization (20-Nov-2020)

1.8b

Closing stock price (20-Nov-2020)

23.0

Cash (30-Jun-2020)

74.5m

EV

1.7b
Atara Biotherapeutics's current market capitalization is $1.8 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

12.7m16.8m24.7m40.3m69.7m79.6m

R&D expense

14.4m56.5m81.2m167.5m216.1m

Operating expense total

27.1m16.8m81.2m121.5m237.1m295.7m

EBIT

(28.2m)(58.4m)(81.2m)(121.5m)(237.1m)(295.7m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

21.9m23.7m48.0m79.2m60.7m74.3m

Prepaid Expenses

1.9m5.9m11.7m13.7m

Inventories

3.9m4.7m

Current Assets

106.0m324.6m260.6m172.2m321.5m273.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(4.1m)(57.2m)(79.0m)(119.5m)(230.7m)(291.0m)

Depreciation and Amortization

48.0k383.0k956.0k3.7m

Accounts Payable

1.0m981.0k2.2m(2.0m)4.2m

Cash From Operating Activities

(37.2m)(60.0m)(87.5m)(179.8m)(235.6m)
USDQ3, 2014

Financial Leverage

-2.4 x
Show all financial metrics

Atara Biotherapeutics Operating Metrics

FY, 2016

Phase I Trials Products

3

Phase II Trials Products

3

Phase III Trials Products

1
Show all operating metrics

Atara Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

D

65/100

SecurityScorecard logo

Atara Biotherapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Atara Biotherapeutics Online and Social Media Presence

Embed Graph

Atara Biotherapeutics Company Culture

  • Overall Culture

    F

    39/100

  • CEO Rating

    F

    30/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Atara Biotherapeutics News and Updates

Thinking about buying stock in CleanSpark, Atara Biotherapeutics, FuelCell Energy, Sorrento Therapeutics, or Plug Power?

NEW YORK, Sept. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSK, ATRA, FCEL, SRNE, and PLUG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Thinking about buying stock in Evofem Biosciences, Village Farms, Atara Biotherapeutics, Cronos Group, or American Airlines?

NEW YORK, May 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, VFF, ATRA, CRON, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

Company to host conference call today at 8:00 a.m. EST Company to host conference call today at 8:00 a.m. EST

Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today named Kristin Yarema as Chief Comm…

Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the …
Show more

Atara Biotherapeutics Blogs

Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting

Long-term follow-up shows all patients who demonstrated sustained disability improvement (SDI) maintained it at all subsequent timepoints 50 percent of patients in the two highest dose Cohorts (3 and 4) demonstrated SDI at 15 months Cohort 4 dose selected for the ongoing randomized placebo-con…

Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

Atara’s allogeneic CAR T therapy leverages the combination of cell intrinsic PD1DNR checkpoint inhibition and 1XX CAR signaling technologies built on the Company’s novel EBV T-cell platform Preclinical findings demonstrate potent antitumor activity, persistence and low toxicity profile of ATA3271…

Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress

 Interim Analysis of the pivotal 302 study (ALLELE) showed tab-cel® in EBV+ PTLD achieved a 50 percent objective response rate and safety consistent with historical data Discussions with FDA confirmed Atara can complete BLA filing with the ALLELE study’s currently enrolled patients with at least…

Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020

Live Conference Call and Webcast at 4:30 p.m. EST SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe disea…

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

Live Conference Call and Webcast at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics , Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral

Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference

Key milestones anticipated across Atara’s four strategic priorities in 2020 Continued investment in EBV T-cell platform to develop off-the-shelf, allogeneic CAR T immunotherapies leveraging favorable EBV T-cell safety, expansion, trafficking and persistence characteristics SOUTH SAN FRANCISCO,
Show more

Atara Biotherapeutics Frequently Asked Questions

  • When was Atara Biotherapeutics founded?

    Atara Biotherapeutics was founded in 2012.

  • Who are Atara Biotherapeutics key executives?

    Atara Biotherapeutics's key executives are Pascal Touchon, Eric Dobmeier and Roy D. Baynes.

  • How many employees does Atara Biotherapeutics have?

    Atara Biotherapeutics has 393 employees.

  • Who are Atara Biotherapeutics competitors?

    Competitors of Atara Biotherapeutics include Rubius Therapeutics, MedDay and Bicycle Therapeutics.

  • Where is Atara Biotherapeutics headquarters?

    Atara Biotherapeutics headquarters is located at Building 83, 611 Gateway Blvd #900, South San Francisco.

  • Where are Atara Biotherapeutics offices?

    Atara Biotherapeutics has offices in South San Francisco, Aurora, New York, Thousand Oaks and in 1 other location.

  • How many offices does Atara Biotherapeutics have?

    Atara Biotherapeutics has 5 offices.